Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
In the past 5 years, the treatment options available to patients with HER2+ breast cancer brain metastasis (BCBM) have expanded. The longer survival of patients with HER2+ BCBM renders understanding the toxicities of local therapies even more important to consider. After reviewing the available lite...
Main Authors: | Tresa M. McGranahan, Alipi V. Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/20/5136 |
Similar Items
-
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
by: Xiaojing Yang, et al.
Published: (2023-01-01) -
Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
by: Xiaoping Ma, et al.
Published: (2022-12-01) -
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
by: Daniel Sanghoon Shin, et al.
Published: (2016-06-01) -
The spatial organization of the epidermal growth factor receptor on the surface of colorectal carcinoma cells
by: Fournier, C
Published: (2015) -
Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
by: Chia-Hsien Shih, et al.
Published: (2024-03-01)